Advertisement
UCB Announces Commercial Availability Of Zilbrysq In U.S. To Treat Generalized Myasthenia Gravis
(RTTNews) - Biopharmaceutical company UCB announced Wednesday that ZILBRYSQ (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
ZILBRYSQ was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.
ZILBRYSQ is available by prescription as a ready-to-use pre-filled syringe that is a once-daily administration. Healthcare providers who prescribe ZILBRYSQ must enroll in the ZILBRYSQ REMS because of the risk of serious meningococcal infections.
Myasthenia gravis is a rare, chronic, autoimmune neuromuscular disease, which is characterized by muscle weakness that worsens after periods of activity and improves after periods of rest.
UCB Announces U.S. Availability Of BIMZELX To Treat Adults With Moderate-to-Severe Plaque Psoriasis
European Shares Flat To Higher As Earnings Pour In
Asian Shares Mostly Lower On Trade Tensions, Weak China Data
South Korean Won Recovers Vs. U.S. Dollar After US-South Korea Trade Deal
Bank Of Japan Keeps Rate On Hold; Lifts Inflation Forecast On Rising Food Prices
Yen Rises After BoJ Rate Decision
Yen Rises Against Majors
